Stock BBIO BRIDGEBIO PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Real-time Estimate Cboe BZX
Other stock markets
 10:22:26 2024-07-05 am EDT 		5-day change 1st Jan Change
24.78 USD -0.86% Intraday chart for BridgeBio Pharma, Inc. -2.05% -38.54%
Jun. 18 BridgeBio Surpasses Interim Analysis Enrollment Target in Limb-Girdle Muscular Dystrophy Trial MT
Jun. 18 BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
PR
BridgeBio Pharma : BBIO – Encaleret for ADH1 – ENDO 2024 Preliminary Findings From an Ongoing Open label Phase 2 Study on Relationship Between Blood and Urinary Calcium in Individuals with Post surgical Hypoparathyroidism
PU
Bridgebio pharma surpasses interim analysis enrollment target and receives u.s. fda rare pediatric disease designation for bbp-418, a potential treatment for limb-girdle muscular dystrophy type 2i/r9
AQ
BridgeBio Surpasses Interim Analysis Enrollment Target in Limb-Girdle Muscular Dystrophy Trial
MT
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
GL
BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
CI
Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
PR
Transcript : BridgeBio Pharma, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
PR
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
GL
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
MT
BridgeBio Pharma Phase 2 Trial of Infigratinib Shows 'Continued Well-Tolerated Safety Profile'; Starts Phase 3 Trial Enrollment
MT
Transcript : BridgeBio Pharma, Inc. - Special Call
BridgeBio Pharma : BBIO – Infigratinib – PROPEL 2 Data Update and ACCEL Program Initiation
PU
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
GL
BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BBIO Stock
  4. News BridgeBio Pharma, Inc.